In Brief: Glaxo v. Novopharm ranitidine
This article was originally published in The Tan Sheet
Executive Summary
Glaxo v. Novopharm ranitidine: April 4 decision by Washington, D.C. federal appeals court upholds the Raleigh, N.C. lower court ruling that Novopharm's ANDA for generic ranitidine Form 1 does not violate Glaxo Wellcome's Zantac (ranitidine Form 2) patents. The appeals court heard oral arguments in Glaxo's appeal on Jan. 7 ("The Tan Sheet" Jan. 13, p. 19)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning